Press for TearScience

A medical device dry-eye treatment that wants to replace eye drops has received U.S. Food and Drug Administration approval.

North Carolina’s TearScience has won FDA approval for its LipiFlow Thermal Pulsation device, which can eliminate gland blockages that in many cases keep the eye from being properly lubricated.

TearScience, Inc., a privately-held medical device company, announced that the Toronto-based Herzig Eye Institute, one of the leading authorities in laser vision correction and advanced cataract and refractive surgery, is the first eye care centre in North America to introduce the innovative LipiFlow®evaporative dry eye disease treatment system, which has received a medical device license from Health Canada.

TearScience, Inc., a privately-held medical device company, today announced the product launch of its LipiView® Ocular Surface Interferometer and LipiFlow® Thermal Pulsation medical devices in Canada. TearScience’s devices were designed to help eye care physicians address a root cause of evaporative dry eye, Meibomian Gland Dysfunction (MGD), which results in a lipid deficiency of the eye’s natural tear film. LipiView® helps physicians visualize the eye’s natural tear film. LipiFlow® is designed to alleviate meibomian gland obstructions by applying a precise combination of directed energy to eyelids during a 12 minute in-office treatment.

Morrisville medical device company TearScience, which raised $44.5 million last year, has signed a lease for roughly 20,000 square feet in a Duke Realty building in Perimeter Park.  The company expects to relocate sometime this summer, CEO Tim Willis said today.